Our previous study labelled FAPI-04 with 225Ac, an alpha particle emitter with a half-life of 10 days for its first decay, and investigated the therapeutic effects of [225Ac]FAPI-04 in FAP-expressing human pancreatic cancer [11]. Here, FAP is linked to familial pancreatic carcinoma.